|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM307118177 |
| 003 |
DE-627 |
| 005 |
20250226205302.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108363
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1023.xml
|
| 035 |
|
|
|a (DE-627)NLM307118177
|
| 035 |
|
|
|a (NLM)32120013
|
| 035 |
|
|
|a (PII)S1521-6616(19)30244-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Chu, Bin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.10.2020
|
| 500 |
|
|
|a Date Revised 19.10.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020. Published by Elsevier Inc.
|
| 520 |
|
|
|a To investigate the role of CD27 in multiple myeloma(MM), bone marrow samples from 165 newly diagnosed MM were analysed by flow cytometry. CD27- group (n = 93) had higher level of plasma cell proportion (37.00% vs 22.50%, p < .05), β2-MG (5.42 vs 3.20 mg/L, p < .05), calcium (2.45 vs 2.28 mmol/L, p < .05),higher percentage of ISS stage III (49.46% vs 22.22%, p < .05) and patients with ≥2 high-risk cytogenetics (24.73% vs 15.28%, p < .05) than CD27+ group (n = 72). After 4 cycles of chemotherapy, the overall response rate in CD27- group were lower than CD27+ group (56.67% vs 73.02%,p < .05). After a median follow-up of 18 months, progression-free survival was significantly shorter in CD27- group than in CD27+ group (22 vs 40 months, p < .05), so was overall survival (median OS not reached, p < .05). Gene sequencing showed more adverse mutations in CD27- group than CD27+ group
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a CD27 antigen
|
| 650 |
|
4 |
|a Cytogenetic
|
| 650 |
|
4 |
|a Gene mutation
|
| 650 |
|
4 |
|a Multiple myeloma
|
| 650 |
|
4 |
|a Overall survival
|
| 650 |
|
7 |
|a Biomarkers, Tumor
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor Receptor Superfamily, Member 7
|2 NLM
|
| 700 |
1 |
|
|a Bao, Li
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yutong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lu, Minqiu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Lei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gao, Shan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fang, Lijuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xiang, Qiuqing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Xi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 213(2020) vom: 28. Apr., Seite 108363
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:213
|g year:2020
|g day:28
|g month:04
|g pages:108363
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108363
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 213
|j 2020
|b 28
|c 04
|h 108363
|